Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase II

MindBio TherapeuticsCSE: MBIO

1 Drug Candidate

MindBio Therapeutics is a clinical-stage biotechnology company developing MB22001, a proprietary titratable form of LSD designed for take-home microdosing. The company's Phase 2B trials in major depressive disorder and advanced-stage cancer distress have reported strong antidepressant effects, with Phase 2a data showing a 72% reduction in depressive symptoms and 58% remission at six months. MindBio is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange.

Drug Pipeline

1

MB22001

LSD
Phase II
Major Depressive Disorder (MDD)

Titratable take-home microdose LSD. Phase 2B in MDD (n=90) and advanced-stage cancer distress (n=40); Phase 2B in PMS/PMDD also approved. Phase 2a showed 72% reduction in depression severity and 58% remission at 6 months.

Quick Facts

Type
Public Biotech
Ticker
CSE: MBIO
Lead Stage
Phase II
Website
Visit